Építés alatt – nem éles oldal
Belépés
Befejeződött1/2. fázis

Universal Anti-Viral Vaccine for Healthy Elderly Adults

A legfontosabb adatok

Ki végzi
Mirror Biologics, Inc.
Hol
Delray Beach, Miami, Tampa és Zephyrhills (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
1/2. fázis
Résztvevők
40 fő vett részt
Kezdés
2021. júl. 12.
Befejezés
2024. nov. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • AlloStim
A regiszteradat frissítve
2025. január 14.

Ki vehet részt

Életkor
65 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 8 feltétel megnézéseKevesebb

Ki vehet részt

  • Males and females who are at least 65 years of age at time of enrollment
  • Good general health *
  • Clinical screening laboratory evaluations (white blood cell (WBC), hemoglobin (Hgb), platelets (PLTs), alanine transaminase (ALT), aspartate transaminase (AST), creatinine (Cr), alkaline phosphatase (ALP), total bilirubin (T. Bili), prothrombin time (PT), and partial thromboplastin time (PTT)) are within acceptable normal reference ranges at the clinical laboratory being used
  • Normal EKG
  • Available for the duration of the study
  • Peripheral veins suitable for blood draw
  • Able to provide consent

Ki nem vehet részt

  • 1. History of autoimmune disease 2. Currently being treated for cancer (other than non-melanoma skin cancer) 3. History of COPD 4. Any clinical condition requiring systemic steroids or any current immunosuppressive therapy 5. HIV positive or any other type of immunodeficiency disorder 6. History of cardiac disease: congestive heart failure > NYHA class 2; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or Digoxin are permitted) 7. Uncontrolled hypertension defined as SBP ≥130 and/or DBP ≥ 80 mm Hg 8. Active clinically serious infections (> grade 2 CTCAE) 9. History of organ transplant or tissue allograft 10. Oral temperature ≥99.0 degrees Fahrenheit (37.2 degrees Celsius). 11. Pulse < 60 or >100 beats per minute. 12. Oxygen saturation <96% 13. Uncontrolled concurrent serious medical or psychiatric illness 14. History of blood transfusion reactions 15. Receipt of any type of influenza vaccine or COVID19 vaccine last dose within two weeks of planned first study drug injection (influenza vaccination after day 28 is permitted); As determined by medical history and physical examination to evaluate acute or ongoing chronic medical diagnoses/conditions that have been present for at least 90 days, which would affect the assessment of safety of subjects. Chronic medical diagnoses/conditions should be stable for the last 60 days (no hospitalizations, emergency room (ER), or urgent care for condition or need for supplemental oxygen). This includes no change in chronic prescription medication, dose, or frequency as a result of deterioration of the chronic medical diagnosis/condition in the 60 days before enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or done for financial reasons, and in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the participating site principal investigator (PI) or appropriate sub-investigator, will not be considered a deviation of this inclusion criterion; Subjects may be on chronic or as needed (prn) medications if, in the opinion of the participating site PI or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity, and do not indicate a worsening of medical diagnosis/condition. Similarly, medication changes subsequent to enrollment and study vaccination are acceptable provided the change was not precipitated by deterioration in the chronic medical condition, and there is no anticipated additional risk to the subject or interference with the evaluation of responses to study vaccination

Helyszínek itt: Egyesült Államok

  • Delray Physician Care CenterDelray Beach, Egyesült Államok
  • Coral Research Clinic & Coral DiagnosticMiami, Egyesült Államok
  • Model ResearchTampa, Egyesült Államok
  • Florida Medical Clinic, LLCZephyrhills, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection against progression of the current outbreak of COVID-19 infection, and any future variants, strains, mutations of the causative SARS-CoV-2 virus as well as protection from any future currently unknown newly emergent novel viruses.

A vizsgálat csoportja

  • VaccinationA vizsgált kezelés

    ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14

    Kezelés: AlloStim

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Efficacy of ALLOSTIM® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly Adults
Publikációk
A regiszteradat frissítve
2025. január 14.